特発性頭蓋内圧亢進症治療の世界市場（～2026年）

• 英文タイトル：Global Idiopathic Intracranial Hypertension Treatment Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY12297
• 出版社/出版日：QYResearch / 2020年11月25日
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、129ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料は特発性頭蓋内圧亢進症治療のグローバル市場について調査・分析したレポートです。種類別（アセタゾラミド、メタゾラミド、フロセミド、トピラマート、その他）市場規模、用途別（病院、クリニック、外来手術センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。
・調査範囲
・エグゼクティブサマリー
・企業別特発性頭蓋内圧亢進症治療の競争状況、市場シェア
・世界の特発性頭蓋内圧亢進症治療市場：種類別市場規模 2015年-2020年（アセタゾラミド、メタゾラミド、フロセミド、トピラマート、その他）
・世界の特発性頭蓋内圧亢進症治療市場：種類別市場規模予測 2021年-2026年（アセタゾラミド、メタゾラミド、フロセミド、トピラマート、その他）
・世界の特発性頭蓋内圧亢進症治療市場：用途別市場規模 2015年-2020年（病院、クリニック、外来手術センター）
・世界の特発性頭蓋内圧亢進症治療市場：用途別市場規模予測 2021年-2026年（病院、クリニック、外来手術センター）
・北米の特発性頭蓋内圧亢進症治療市場分析：米国、カナダ
・ヨーロッパの特発性頭蓋内圧亢進症治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの特発性頭蓋内圧亢進症治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の特発性頭蓋内圧亢進症治療市場分析：メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの特発性頭蓋内圧亢進症治療市場分析：トルコ、サウジアラビア、UAE等
・企業情報（企業概要、製品概要、販売量、企業動向）
- 掲載企業（変更可能性あり）：Avkare, Inc、FDC、Heritage Pharmaceuticals Inc、Ingenus Pharmaceuticals、Janssen - Cilag Pharmaceuticals SA、Lannett Company,、Medtronic、MercuryPharma、Nostrum Laboratories Inc、Novast Holdings Ltd.、Sanofi、SGPharma Pvt. Ltd.、Sophysa、Taro Pharmaceutical Industries Ltd.、Teva Pharmaceutical Industries Ltd、West-Ward Pharmaceutical、Zydus Pharmaceuticals
・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論

Idiopathic intracranial hypertension is characterized by a buildup of the cerebrospinal fluid causing increase in the blood volume in vessels surrounding the brain and increase in brain swelling. The increase in salt intake causes water retention in the body together with fat adding on to the calories thereby hindering the weight loss usually advised. Intracranial hypertension can also cause problem with body temperature control when there is overexposure to the sun and its heat.

Market Analysis and Insights: Global Idiopathic Intracranial Hypertension Treatment Market
The global Idiopathic Intracranial Hypertension Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Idiopathic Intracranial Hypertension Treatment Scope and Market Size
Idiopathic Intracranial Hypertension Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Idiopathic Intracranial Hypertension Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Avkare, Inc
FDC
Heritage Pharmaceuticals Inc
Ingenus Pharmaceuticals
Janssen – Cilag Pharmaceuticals SA
Lannett Company,
Medtronic
MercuryPharma
Nostrum Laboratories Inc
Novast Holdings Ltd.
Sanofi
SGPharma Pvt. Ltd.
Sophysa
Taro Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd
West-Ward Pharmaceutical
Zydus Pharmaceuticals

Market segment by Type, the product can be split into
Acetazolamide
Methazolamide
Furosemide
Topiramate
Others
Market segment by Application, split into
Hospital
Clinics
Ambulatory Surgery Centers

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Idiopathic Intracranial Hypertension Treatment Revenue
1.4 Market by Type
1.4.1 Global Idiopathic Intracranial Hypertension Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Acetazolamide
1.4.3 Methazolamide
1.4.4 Furosemide
1.4.5 Topiramate
1.4.6 Others
1.5 Market by Application
1.5.1 Global Idiopathic Intracranial Hypertension Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinics
1.5.4 Ambulatory Surgery Centers
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Idiopathic Intracranial Hypertension Treatment Market Perspective (2015-2026)
2.2 Global Idiopathic Intracranial Hypertension Treatment Growth Trends by Regions
2.2.1 Idiopathic Intracranial Hypertension Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Idiopathic Intracranial Hypertension Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Idiopathic Intracranial Hypertension Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Idiopathic Intracranial Hypertension Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Idiopathic Intracranial Hypertension Treatment Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Idiopathic Intracranial Hypertension Treatment Players by Market Size
3.1.1 Global Top Idiopathic Intracranial Hypertension Treatment Players by Revenue (2015-2020)
3.1.2 Global Idiopathic Intracranial Hypertension Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Idiopathic Intracranial Hypertension Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Idiopathic Intracranial Hypertension Treatment Market Concentration Ratio
3.2.1 Global Idiopathic Intracranial Hypertension Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Idiopathic Intracranial Hypertension Treatment Revenue in 2019
3.3 Idiopathic Intracranial Hypertension Treatment Key Players Head office and Area Served
3.4 Key Players Idiopathic Intracranial Hypertension Treatment Product Solution and Service
3.5 Date of Enter into Idiopathic Intracranial Hypertension Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Idiopathic Intracranial Hypertension Treatment Historic Market Size by Type (2015-2020)
4.2 Global Idiopathic Intracranial Hypertension Treatment Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020)
5.2 Global Idiopathic Intracranial Hypertension Treatment Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Idiopathic Intracranial Hypertension Treatment Market Size (2015-2020)
6.2 Idiopathic Intracranial Hypertension Treatment Key Players in North America (2019-2020)
6.3 North America Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020)
6.4 North America Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020)

7 Europe
7.1 Europe Idiopathic Intracranial Hypertension Treatment Market Size (2015-2020)
7.2 Idiopathic Intracranial Hypertension Treatment Key Players in Europe (2019-2020)
7.3 Europe Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020)
7.4 Europe Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020)

8 China
8.1 China Idiopathic Intracranial Hypertension Treatment Market Size (2015-2020)
8.2 Idiopathic Intracranial Hypertension Treatment Key Players in China (2019-2020)
8.3 China Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020)
8.4 China Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020)

9 Japan
9.1 Japan Idiopathic Intracranial Hypertension Treatment Market Size (2015-2020)
9.2 Idiopathic Intracranial Hypertension Treatment Key Players in Japan (2019-2020)
9.3 Japan Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020)
9.4 Japan Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Idiopathic Intracranial Hypertension Treatment Market Size (2015-2020)
10.2 Idiopathic Intracranial Hypertension Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020)

11 India
11.1 India Idiopathic Intracranial Hypertension Treatment Market Size (2015-2020)
11.2 Idiopathic Intracranial Hypertension Treatment Key Players in India (2019-2020)
11.3 India Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020)
11.4 India Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Idiopathic Intracranial Hypertension Treatment Market Size (2015-2020)
12.2 Idiopathic Intracranial Hypertension Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020)
12.4 Central & South America Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Avkare, Inc
13.1.1 Avkare, Inc Company Details
13.1.2 Avkare, Inc Business Overview
13.1.3 Avkare, Inc Idiopathic Intracranial Hypertension Treatment Introduction
13.1.4 Avkare, Inc Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020))
13.1.5 Avkare, Inc Recent Development
13.2 FDC
13.2.1 FDC Company Details
13.2.2 FDC Business Overview
13.2.3 FDC Idiopathic Intracranial Hypertension Treatment Introduction
13.2.4 FDC Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
13.2.5 FDC Recent Development
13.3 Heritage Pharmaceuticals Inc
13.3.1 Heritage Pharmaceuticals Inc Company Details
13.3.2 Heritage Pharmaceuticals Inc Business Overview
13.3.3 Heritage Pharmaceuticals Inc Idiopathic Intracranial Hypertension Treatment Introduction
13.3.4 Heritage Pharmaceuticals Inc Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
13.3.5 Heritage Pharmaceuticals Inc Recent Development
13.4 Ingenus Pharmaceuticals
13.4.1 Ingenus Pharmaceuticals Company Details
13.4.2 Ingenus Pharmaceuticals Business Overview
13.4.3 Ingenus Pharmaceuticals Idiopathic Intracranial Hypertension Treatment Introduction
13.4.4 Ingenus Pharmaceuticals Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
13.4.5 Ingenus Pharmaceuticals Recent Development
13.5 Janssen – Cilag Pharmaceuticals SA
13.5.1 Janssen – Cilag Pharmaceuticals SA Company Details
13.5.2 Janssen – Cilag Pharmaceuticals SA Business Overview
13.5.3 Janssen – Cilag Pharmaceuticals SA Idiopathic Intracranial Hypertension Treatment Introduction
13.5.4 Janssen – Cilag Pharmaceuticals SA Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
13.5.5 Janssen – Cilag Pharmaceuticals SA Recent Development
13.6 Lannett Company,
13.6.1 Lannett Company, Company Details
13.6.2 Lannett Company, Business Overview
13.6.3 Lannett Company, Idiopathic Intracranial Hypertension Treatment Introduction
13.6.4 Lannett Company, Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
13.6.5 Lannett Company, Recent Development
13.7 Medtronic
13.7.1 Medtronic Company Details
13.7.2 Medtronic Business Overview
13.7.3 Medtronic Idiopathic Intracranial Hypertension Treatment Introduction
13.7.4 Medtronic Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
13.7.5 Medtronic Recent Development
13.8 MercuryPharma
13.8.1 MercuryPharma Company Details
13.8.2 MercuryPharma Business Overview
13.8.3 MercuryPharma Idiopathic Intracranial Hypertension Treatment Introduction
13.8.4 MercuryPharma Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
13.8.5 MercuryPharma Recent Development
13.9 Nostrum Laboratories Inc
13.9.1 Nostrum Laboratories Inc Company Details
13.9.2 Nostrum Laboratories Inc Business Overview
13.9.3 Nostrum Laboratories Inc Idiopathic Intracranial Hypertension Treatment Introduction
13.9.4 Nostrum Laboratories Inc Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
13.9.5 Nostrum Laboratories Inc Recent Development
13.10 Novast Holdings Ltd.
13.10.1 Novast Holdings Ltd. Company Details
13.10.2 Novast Holdings Ltd. Business Overview
13.10.3 Novast Holdings Ltd. Idiopathic Intracranial Hypertension Treatment Introduction
13.10.4 Novast Holdings Ltd. Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
13.10.5 Novast Holdings Ltd. Recent Development
13.11 Sanofi
10.11.1 Sanofi Company Details
10.11.2 Sanofi Business Overview
10.11.3 Sanofi Idiopathic Intracranial Hypertension Treatment Introduction
10.11.4 Sanofi Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
10.11.5 Sanofi Recent Development
13.12 SGPharma Pvt. Ltd.
10.12.1 SGPharma Pvt. Ltd. Company Details
10.12.2 SGPharma Pvt. Ltd. Business Overview
10.12.3 SGPharma Pvt. Ltd. Idiopathic Intracranial Hypertension Treatment Introduction
10.12.4 SGPharma Pvt. Ltd. Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
10.12.5 SGPharma Pvt. Ltd. Recent Development
13.13 Sophysa
10.13.1 Sophysa Company Details
10.13.2 Sophysa Business Overview
10.13.3 Sophysa Idiopathic Intracranial Hypertension Treatment Introduction
10.13.4 Sophysa Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
10.13.5 Sophysa Recent Development
13.14 Taro Pharmaceutical Industries Ltd.
10.14.1 Taro Pharmaceutical Industries Ltd. Company Details
10.14.2 Taro Pharmaceutical Industries Ltd. Business Overview
10.14.3 Taro Pharmaceutical Industries Ltd. Idiopathic Intracranial Hypertension Treatment Introduction
10.14.4 Taro Pharmaceutical Industries Ltd. Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
10.14.5 Taro Pharmaceutical Industries Ltd. Recent Development
13.15 Teva Pharmaceutical Industries Ltd
10.15.1 Teva Pharmaceutical Industries Ltd Company Details
10.15.2 Teva Pharmaceutical Industries Ltd Business Overview
10.15.3 Teva Pharmaceutical Industries Ltd Idiopathic Intracranial Hypertension Treatment Introduction
10.15.4 Teva Pharmaceutical Industries Ltd Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
10.15.5 Teva Pharmaceutical Industries Ltd Recent Development
13.16 West-Ward Pharmaceutical
10.16.1 West-Ward Pharmaceutical Company Details
10.16.2 West-Ward Pharmaceutical Business Overview
10.16.3 West-Ward Pharmaceutical Idiopathic Intracranial Hypertension Treatment Introduction
10.16.4 West-Ward Pharmaceutical Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
10.16.5 West-Ward Pharmaceutical Recent Development
13.17 Zydus Pharmaceuticals
10.17.1 Zydus Pharmaceuticals Company Details
10.17.2 Zydus Pharmaceuticals Business Overview
10.17.3 Zydus Pharmaceuticals Idiopathic Intracranial Hypertension Treatment Introduction
10.17.4 Zydus Pharmaceuticals Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020)
10.17.5 Zydus Pharmaceuticals Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Idiopathic Intracranial Hypertension Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Idiopathic Intracranial Hypertension Treatment Revenue
Table 3. Ranking of Global Top Idiopathic Intracranial Hypertension Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Idiopathic Intracranial Hypertension Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Acetazolamide
Table 6. Key Players of Methazolamide
Table 7. Key Players of Furosemide
Table 8. Key Players of Topiramate
Table 9. Key Players of Others
Table 10. Global Idiopathic Intracranial Hypertension Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 11. Global Idiopathic Intracranial Hypertension Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 12. Global Idiopathic Intracranial Hypertension Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 13. Global Idiopathic Intracranial Hypertension Treatment Market Share by Regions (2015-2020)
Table 14. Global Idiopathic Intracranial Hypertension Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 15. Global Idiopathic Intracranial Hypertension Treatment Market Share by Regions (2021-2026)
Table 16. Market Top Trends
Table 17. Key Drivers: Impact Analysis
Table 18. Key Challenges
Table 19. Idiopathic Intracranial Hypertension Treatment Market Growth Strategy
Table 20. Main Points Interviewed from Key Idiopathic Intracranial Hypertension Treatment Players
Table 21. Global Idiopathic Intracranial Hypertension Treatment Revenue by Players (2015-2020) (Million US$)
Table 22. Global Idiopathic Intracranial Hypertension Treatment Market Share by Players (2015-2020)
Table 23. Global Top Idiopathic Intracranial Hypertension Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Intracranial Hypertension Treatment as of 2019)
Table 24. Global Idiopathic Intracranial Hypertension Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Idiopathic Intracranial Hypertension Treatment Product Solution and Service
Table 27. Date of Enter into Idiopathic Intracranial Hypertension Treatment Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020) (Million US$)
Table 30. Global Idiopathic Intracranial Hypertension Treatment Market Size Share by Type (2015-2020)
Table 31. Global Idiopathic Intracranial Hypertension Treatment Revenue Market Share by Type (2021-2026)
Table 32. Global Idiopathic Intracranial Hypertension Treatment Market Size Share by Application (2015-2020)
Table 33. Global Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020) (Million US$)
Table 34. Global Idiopathic Intracranial Hypertension Treatment Market Size Share by Application (2021-2026)
Table 35. North America Key Players Idiopathic Intracranial Hypertension Treatment Revenue (2019-2020) (Million US$)
Table 36. North America Key Players Idiopathic Intracranial Hypertension Treatment Market Share (2019-2020)
Table 37. North America Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020) (Million US$)
Table 38. North America Idiopathic Intracranial Hypertension Treatment Market Share by Type (2015-2020)
Table 39. North America Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020) (Million US$)
Table 40. North America Idiopathic Intracranial Hypertension Treatment Market Share by Application (2015-2020)
Table 41. Europe Key Players Idiopathic Intracranial Hypertension Treatment Revenue (2019-2020) (Million US$)
Table 42. Europe Key Players Idiopathic Intracranial Hypertension Treatment Market Share (2019-2020)
Table 43. Europe Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020) (Million US$)
Table 44. Europe Idiopathic Intracranial Hypertension Treatment Market Share by Type (2015-2020)
Table 45. Europe Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020) (Million US$)
Table 46. Europe Idiopathic Intracranial Hypertension Treatment Market Share by Application (2015-2020)
Table 47. China Key Players Idiopathic Intracranial Hypertension Treatment Revenue (2019-2020) (Million US$)
Table 48. China Key Players Idiopathic Intracranial Hypertension Treatment Market Share (2019-2020)
Table 49. China Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020) (Million US$)
Table 50. China Idiopathic Intracranial Hypertension Treatment Market Share by Type (2015-2020)
Table 51. China Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020) (Million US$)
Table 52. China Idiopathic Intracranial Hypertension Treatment Market Share by Application (2015-2020)
Table 53. Japan Key Players Idiopathic Intracranial Hypertension Treatment Revenue (2019-2020) (Million US$)
Table 54. Japan Key Players Idiopathic Intracranial Hypertension Treatment Market Share (2019-2020)
Table 55. Japan Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020) (Million US$)
Table 56. Japan Idiopathic Intracranial Hypertension Treatment Market Share by Type (2015-2020)
Table 57. Japan Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020) (Million US$)
Table 58. Japan Idiopathic Intracranial Hypertension Treatment Market Share by Application (2015-2020)
Table 59. Southeast Asia Key Players Idiopathic Intracranial Hypertension Treatment Revenue (2019-2020) (Million US$)
Table 60. Southeast Asia Key Players Idiopathic Intracranial Hypertension Treatment Market Share (2019-2020)
Table 61. Southeast Asia Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020) (Million US$)
Table 62. Southeast Asia Idiopathic Intracranial Hypertension Treatment Market Share by Type (2015-2020)
Table 63. Southeast Asia Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020) (Million US$)
Table 64. Southeast Asia Idiopathic Intracranial Hypertension Treatment Market Share by Application (2015-2020)
Table 65. India Key Players Idiopathic Intracranial Hypertension Treatment Revenue (2019-2020) (Million US$)
Table 66. India Key Players Idiopathic Intracranial Hypertension Treatment Market Share (2019-2020)
Table 67. India Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020) (Million US$)
Table 68. India Idiopathic Intracranial Hypertension Treatment Market Share by Type (2015-2020)
Table 69. India Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020) (Million US$)
Table 70. India Idiopathic Intracranial Hypertension Treatment Market Share by Application (2015-2020)
Table 71. Central & South America Key Players Idiopathic Intracranial Hypertension Treatment Revenue (2019-2020) (Million US$)
Table 72. Central & South America Key Players Idiopathic Intracranial Hypertension Treatment Market Share (2019-2020)
Table 73. Central & South America Idiopathic Intracranial Hypertension Treatment Market Size by Type (2015-2020) (Million US$)
Table 74. Central & South America Idiopathic Intracranial Hypertension Treatment Market Share by Type (2015-2020)
Table 75. Central & South America Idiopathic Intracranial Hypertension Treatment Market Size by Application (2015-2020) (Million US$)
Table 76. Central & South America Idiopathic Intracranial Hypertension Treatment Market Share by Application (2015-2020)
Table 77. Avkare, Inc Company Details
Table 78. Avkare, Inc Business Overview
Table 79. Avkare, Inc Product
Table 80. Avkare, Inc Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 81. Avkare, Inc Recent Development
Table 82. FDC Company Details
Table 83. FDC Business Overview
Table 84. FDC Product
Table 85. FDC Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 86. FDC Recent Development
Table 87. Heritage Pharmaceuticals Inc Company Details
Table 88. Heritage Pharmaceuticals Inc Business Overview
Table 89. Heritage Pharmaceuticals Inc Product
Table 90. Heritage Pharmaceuticals Inc Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 91. Heritage Pharmaceuticals Inc Recent Development
Table 92. Ingenus Pharmaceuticals Company Details
Table 93. Ingenus Pharmaceuticals Business Overview
Table 94. Ingenus Pharmaceuticals Product
Table 95. Ingenus Pharmaceuticals Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 96. Ingenus Pharmaceuticals Recent Development
Table 97. Janssen - Cilag Pharmaceuticals SA Company Details
Table 98. Janssen - Cilag Pharmaceuticals SA Business Overview
Table 99. Janssen - Cilag Pharmaceuticals SA Product
Table 100. Janssen - Cilag Pharmaceuticals SA Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 101. Janssen - Cilag Pharmaceuticals SA Recent Development
Table 102. Lannett Company, Company Details
Table 103. Lannett Company, Business Overview
Table 104. Lannett Company, Product
Table 105. Lannett Company, Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 106. Lannett Company, Recent Development
Table 107. Medtronic Company Details
Table 108. Medtronic Business Overview
Table 109. Medtronic Product
Table 110. Medtronic Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 111. Medtronic Recent Development
Table 112. MercuryPharma Business Overview
Table 113. MercuryPharma Product
Table 114. MercuryPharma Company Details
Table 115. MercuryPharma Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 116. MercuryPharma Recent Development
Table 117. Nostrum Laboratories Inc Company Details
Table 118. Nostrum Laboratories Inc Business Overview
Table 119. Nostrum Laboratories Inc Product
Table 120. Nostrum Laboratories Inc Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 121. Nostrum Laboratories Inc Recent Development
Table 122. Novast Holdings Ltd. Company Details
Table 123. Novast Holdings Ltd. Business Overview
Table 124. Novast Holdings Ltd. Product
Table 125. Novast Holdings Ltd. Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 126. Novast Holdings Ltd. Recent Development
Table 127. Sanofi Company Details
Table 128. Sanofi Business Overview
Table 129. Sanofi Product
Table 130. Sanofi Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 131. Sanofi Recent Development
Table 132. SGPharma Pvt. Ltd. Company Details
Table 133. SGPharma Pvt. Ltd. Business Overview
Table 134. SGPharma Pvt. Ltd. Product
Table 135. SGPharma Pvt. Ltd. Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 136. SGPharma Pvt. Ltd. Recent Development
Table 137. Sophysa Company Details
Table 138. Sophysa Business Overview
Table 139. Sophysa Product
Table 140. Sophysa Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 141. Sophysa Recent Development
Table 142. Taro Pharmaceutical Industries Ltd. Company Details
Table 143. Taro Pharmaceutical Industries Ltd. Business Overview
Table 144. Taro Pharmaceutical Industries Ltd. Product
Table 145. Taro Pharmaceutical Industries Ltd. Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 146. Taro Pharmaceutical Industries Ltd. Recent Development
Table 147. Teva Pharmaceutical Industries Ltd Company Details
Table 148. Teva Pharmaceutical Industries Ltd Business Overview
Table 149. Teva Pharmaceutical Industries Ltd Product
Table 150. Teva Pharmaceutical Industries Ltd Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 151. Teva Pharmaceutical Industries Ltd Recent Development
Table 152. West-Ward Pharmaceutical Company Details
Table 153. West-Ward Pharmaceutical Business Overview
Table 154. West-Ward Pharmaceutical Product
Table 155. West-Ward Pharmaceutical Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 156. West-Ward Pharmaceutical Recent Development
Table 157. Zydus Pharmaceuticals Company Details
Table 158. Zydus Pharmaceuticals Business Overview
Table 159. Zydus Pharmaceuticals Product
Table 160. Zydus Pharmaceuticals Revenue in Idiopathic Intracranial Hypertension Treatment Business (2015-2020) (Million US$)
Table 161. Zydus Pharmaceuticals Recent Development
Table 162. Research Programs/Design for This Report
Table 163. Key Data Information from Secondary Sources
Table 164. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Idiopathic Intracranial Hypertension Treatment Market Share by Type: 2020 VS 2026
Figure 2. Acetazolamide Features
Figure 3. Methazolamide Features
Figure 4. Furosemide Features
Figure 5. Topiramate Features
Figure 6. Others Features
Figure 7. Global Idiopathic Intracranial Hypertension Treatment Market Share by Application: 2020 VS 2026
Figure 8. Hospital Case Studies
Figure 9. Clinics Case Studies
Figure 10. Ambulatory Surgery Centers Case Studies
Figure 11. Idiopathic Intracranial Hypertension Treatment Report Years Considered
Figure 12. Global Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Idiopathic Intracranial Hypertension Treatment Market Share by Regions: 2020 VS 2026
Figure 14. Global Idiopathic Intracranial Hypertension Treatment Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Idiopathic Intracranial Hypertension Treatment Market Share by Players in 2019
Figure 17. Global Top Idiopathic Intracranial Hypertension Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Intracranial Hypertension Treatment as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Idiopathic Intracranial Hypertension Treatment Revenue in 2019
Figure 19. North America Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Idiopathic Intracranial Hypertension Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed

以下、関連資料のご紹介

特発性頭蓋内圧亢進症治療薬の世界市場（～2026年）

Global Idiopathic Intracranial Hypertension Therapeutics Market Size, Status and Forecast 2020-2026
MRC2-11QY12296 2020年11月25日 98Pages
当調査資料は特発性頭蓋内圧亢進症治療薬のグローバル市場について調査・分析したレポートです。種類別（アセタゾラミド、フロセミド、トピラマート、オクトレオチド）市場規模、用途別（病院薬局、小売薬局、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、ア...

全身性特発性若年性関節炎治療の世界市場（～2026年）

Global Systemic Idiopathic Juvenile Arthritis Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY04784 2020年11月20日 92Pages
当調査資料は全身性特発性若年性関節炎治療のグローバル市場について調査・分析したレポートです。種類別（アダリムマブバイオシミラー、カナキヌマブ、ゴリムマブ、トシリズマブバイオシミラー、その他）市場規模、用途別（クリニック、病院、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス...

頭蓋内出血診断・治療の世界市場（～2026年）

Global Intracranial Hemorrhage Diagnosis and Treatment Market Size, Status and Forecast 2020-2026
MRC2-11QY12412 2020年11月25日 91Pages
当調査資料は頭蓋内出血診断・治療のグローバル市場について調査・分析したレポートです。種類別（装置、薬剤、その他）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、...

慢性特発性骨髄線維症の世界市場（～2026年）

Global Chronic Idiopathic Myelofibrosis Market Size, Status and Forecast 2020-2026
MRC2-11QY11363 2020年11月25日 96Pages
当調査資料は慢性特発性骨髄線維症のグローバル市場について調査・分析したレポートです。種類別（化学療法、生物学的療法、その他）市場規模、用途別（病院、クリニック、研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、...

特発性低身長治療薬の世界市場（～2026年）

Global Idiopathic Short Stature Drug Market Insights and Forecast to 2026
MRC2-11QY01538 2020年11月20日 111Pages
当調査資料は特発性低身長治療薬のグローバル市場について調査・分析したレポートです。種類別（BBT-031、MMP-0201、ソマトロピン、ソマトロピンS、その他）市場規模、用途別（研究センター、病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、...

慢性特発性便秘（CIC）治療薬の世界市場（～2026年）

Global Chronic Idiopathic Constipation (CIC) Drugs Market Insights and Forecast to 2026
MRC2-11QY00261 2020年11月20日 114Pages
当調査資料は慢性特発性便秘（CIC）治療薬のグローバル市場について調査・分析したレポートです。種類別（ルビプロストン、リナクロチド、その他）市場規模、用途別（病院・診療所、外来外科センター、介護センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、...

慢性血栓塞栓性肺高血圧症（CTEPH）の世界市場（～2026年）

Global Chronic Thromboembolic Pulmonary Hypertension Market Size, Status and Forecast 2020-2026
MRC2-11QY11373 2020年11月25日 99Pages
当調査資料は慢性血栓塞栓性肺高血圧症（CTEPH）のグローバル市場について調査・分析したレポートです。種類別（経胸壁心エコー検査（TTE）、換気灌流（V/Q）スキャン、肺血管造影、心臓カテーテル検査、コンピューター断層撮影（CT）肺血管造影、その他）市場規模、用途別（病院、外来手術センター、その他）...

多関節若年性特発性関節炎治療薬の世界市場（～2026年）

Global Polyarticular Juvenile Idiopathic Arthritis Drug Market Insights and Forecast to 2026
MRC2-11QY13950 2020年11月30日 111Pages
当調査資料は多関節若年性特発性関節炎治療薬のグローバル市場について調査・分析したレポートです。種類別（エタネルセプトバイオシミラー、トシリズマブバイオシミラー、サリルマブ、アダリムマブバイオシミラー、その他）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ド...

高血圧治療薬の世界市場（～2026年）

Global Hypertension Drugs Market Insights and Forecast to 2026
MRC2-11QY01518 2020年11月20日 117Pages
当調査資料は高血圧治療薬のグローバル市場について調査・分析したレポートです。種類別（カルシウム拮抗薬、利尿薬、ベータ遮断薬、血管拡張薬、アンジオテンシン変換酵素阻害薬、アルファ遮断薬、アンジオテンシン受容体遮断薬、レニン阻害薬）市場規模、用途別（病院、診療所、その他）市場規模、地域別（北米、米国、カ...

肺動脈性肺高血圧症（PAH）の世界市場（～2026年）

Global Pulmonary Arterial Hypertension (PAH) Market Size, Status and Forecast 2020-2026
MRC2-11QY04414 2020年11月20日 95Pages
当調査資料は肺動脈性肺高血圧症（PAH）のグローバル市場について調査・分析したレポートです。種類別（プロスタサイクリンおよびプロスタサイクリン類似体、SGC刺激剤、ERA、PDE-5）市場規模、用途別（病院、クリニック）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イ...

特発性頭蓋内圧亢進症治療薬の世界市場（～2026年） A drug used to treat idiopathic intracranial hypertension. Market Analysis and Insights: Global Idiopathic Intracranial Hypertension Therapeutics Market The global Idiopathic Intracranial Hypertension Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020,…
頭蓋内出血診断・治療の世界市場（～2026年） Bleeding or haemorrhages loss of blood from the circulatory system which may be internal or external due to variety of conditions such as trauma, tissue damage due to surgery, accidents, cuts etc. Generally loss of 10–15% of the total blood volume does not cause serious mental problems and can be to…
全身性特発性若年性関節炎治療の世界市場（～2026年） Market Analysis and Insights: Global Systemic Idiopathic Juvenile Arthritis Treatment Market The global Systemic Idiopathic Juvenile Arthritis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Systemic Idiopath…
肺動脈性肺高血圧症（PAH）の世界市場（～2026年） Market Analysis and Insights: Global Pulmonary Arterial Hypertension (PAH) Market The global Pulmonary Arterial Hypertension (PAH) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Pulmonary Arterial Hypertension (PAH) S…
慢性特発性骨髄線維症の世界市場（～2026年） Idiopathic myelofibrosis is a chronic myelo-proliferative disorder and characterized by abnormal mutation of stem cells. This abnormal mutation of stem cells and excessive production of platelets result in development of fibrous tissues within the bone-marrow. This factor would ultimately negatively…